Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185)
:2185
Want to see HK:2185 full AI Analyst Report?
2185 Stock Chart & Stats
HK$5.71
HK$0.03(1.94%)
At close: 4:00 PM EST
HK$5.71
HK$0.03(1.94%)
Day’s Range― - ―
52-Week RangeHK$2.43 - HK$10.77
Previous CloseN/A
Volume27.00K
Average Volume (3M)2.14M
Market Cap
HK$657.23M
Enterprise ValueHK$414.13M
Total Cash (Recent Filing)HK$248.63M
Total Debt (Recent Filing)HK$12.73M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding235,703,410
10 Day Avg. Volume3,698,147
30 Day Avg. Volume2,141,365
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)2.91
Price to Sales (P/S)28.92
P/FCF Ratio-17.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$2.07B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong SolvencyVery low leverage gives the company structural financial flexibility to fund R&D and bridge development cycles without immediate default risk. Over 2-6 months this supports operations and strategic options (licensing, partner deals or measured fundraising) despite ongoing losses.
Revenue Rebound In 2025A meaningful revenue rebound suggests emerging commercial traction or successful early monetization. Persisting revenue growth over quarters would indicate the business moving from R&D toward repeatable sales, improving prospects for margin expansion and lower funding dependence long term.
Regenerative-medicine R&D FocusOperating in regenerative medicine exposes the company to structural industry tailwinds, high barriers to entry and value-accretive IP or partnership opportunities. Successful clinical or regulatory milestones could create durable competitive advantages and long-term commercial upside.
Bears Say
Persistent Operating LossesLarge, persistent operating losses indicate the core operations are not yet self-sustaining. Over months this erodes equity, forces management to prioritize cash conservation, and increases reliance on external funding, which can dilute shareholders and constrain long-term strategic investments.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow reveals ongoing cash burn to fund R&D and ops. This structural cash shortfall means the company must access financing or partnerships; if markets tighten, the business could face disrupted programs or delayed commercialization timelines.
Eroding Equity & Negative Returns On CapitalDeclining equity and sustained negative ROE show capital is not generating returns and the balance sheet buffer is shrinking. Over a multi-month horizon this increases vulnerability to shocks, limits borrowing capacity, and raises the cost or likelihood of dilutive financing to sustain operations.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H News
2185 FAQ
What was Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H lowest stock price was HK$2.43 and its highest was HK$10.77 in the past 12 months.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap is HK$657.23M.
When is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Jul 31, 2026 which is in 43 days.
How were Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s earnings last quarter?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.193 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.193.
Is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H have?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H has 235,703,410 shares outstanding.
What happened to Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H reported an EPS of -HK$0.193 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.308%.
Which hedge fund is a major shareholder of Shanghai Bio-Heart Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2185
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
387.50%
12-Months-Change
Fundamentals
Return on Equity
-15.19%
Trailing 12-Months
Asset Growth
18.74%
Trailing 12-Months
Company Description
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Based in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies to address conditions like coronary artery diseases and persistent, uncontrolled high blood pressure. The company's product pipeline features Bioheart, a BRS system designed for percutaneous coronary interventions for coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and a sirolimus drug-eluting balloon catheter intended for managing in-stent restenosis. Furthermore, the company has partnered with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was established in 2014 and maintains its headquarters in Shanghai, China.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) Earnings & Revenues
Technical Analysis
CARsgen Therapeutics Holdings Ltd.
―
Mabpharm Limited
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Wuhan YZY Biopharma Co., Ltd. Class H
―
Sunho Biologics,Inc.
―
Options Prices
Currently, No data available
---